Literature DB >> 11036940

Regulation of the pituitary somatotroph cell by GHRH and its receptor.

K E Mayo1, T Miller, V DeAlmeida, P Godfrey, J Zheng, S R Cunha.   

Abstract

Hormones from the hypothalamus mediate interactions between the nervous and endocrine systems by controlling the activity of specific target cells in the anterior pituitary gland. The hypothalamic peptide, growth hormone-releasing hormone (GHRH), acts on pituitary somatotroph cells to stimulate their proliferation during development and to regulate their ability to produce and secrete growth hormone (GH). These actions are mediated by a recently identified receptor for GHRH that belongs to family B-III of the G protein-coupled receptor superfamily. The rat GHRH receptor is expressed predominantly in the pituitary gland and in somatotroph cells. To investigate this tissue- and cell-specific expression, the receptor gene has been cloned and characterized. The receptor gene promoter is selectively expressed in pituitary cells and is regulated by the pituitary-specific transcription factor Pit-1. There is a sexual dimorphism in GHRH receptor expression in the rat pituitary, suggesting regulation by gonadal steroids. In addition, glucocorticoids are potent positive regulators of GHRH receptor gene expression. Substantial evidence points to an important role for GHRH in regulating the proliferation and functional activity of the somatotroph cell. This is best observed in the dwarf little mouse, which harbors a mutation in the extracellular domain of the GHRH receptor that abolishes the receptor's hormone-binding and signaling properties, resulting in severe somatotroph hypoplasia. Complementary studies in transgenic mice overexpressing the ligand GHRH reveal corresponding somatotroph hyperplasia. Consistent with these observations, GHRH potently activates the MAP kinase pathway in pituitary somatotroph cells. To better understand the hormone-binding and signaling properties of the GHRH receptor, mutant and chimeric receptors have been analyzed to define domains important for GHRH interaction. The GHRH receptor signals predominantly through cAMP-dependent pathways; however, a variant form of the GHRH receptor with an insertion into the third intracellular domain, generated through alternative RNA processing, binds GHRH but fails to signal, suggesting potential modulation of receptor function at a post-transcriptional level. This chapter will integrate these basic investigations of GHRH and its receptor with current information on the involvement of the GHRH signaling system in human diseases of GH secretion and growth.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036940

Source DB:  PubMed          Journal:  Recent Prog Horm Res        ISSN: 0079-9963


  24 in total

Review 1.  Ion channels and signaling in the pituitary gland.

Authors:  Stanko S Stojilkovic; Joël Tabak; Richard Bertram
Journal:  Endocr Rev       Date:  2010-07-21       Impact factor: 19.871

2.  Foxo1 Is Required for Normal Somatotrope Differentiation.

Authors:  Jyoti Kapali; Brock E Kabat; Kelly L Schmidt; Caitlin E Stallings; Mason Tippy; Deborah O Jung; Brian S Edwards; Leah B Nantie; Lori T Raeztman; Amy M Navratil; Buffy S Ellsworth
Journal:  Endocrinology       Date:  2016-09-15       Impact factor: 4.736

3.  Pituitary miRNAs target GHRHR splice variants to regulate GH synthesis by mediating different intracellular signalling pathways.

Authors:  Yunyun Cheng; Ting Chen; Jie Song; Zhaohui Teng; Chunli Wang; Siyao Wang; Guanhong Lu; Tianqi Feng; Qien Qi; Qianyun Xi; Songcai Liu; Linlin Hao; Yongliang Zhang
Journal:  RNA Biol       Date:  2020-06-19       Impact factor: 4.652

4.  Homologous and heterologous in vitro regulation of pituitary receptors for somatostatin, growth hormone (GH)-releasing hormone, and ghrelin in a nonhuman primate (Papio anubis).

Authors:  Jose Córdoba-Chacón; Manuel D Gahete; Justo P Castaño; Rhonda D Kineman; Raul M Luque
Journal:  Endocrinology       Date:  2011-11-22       Impact factor: 4.736

5.  Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly.

Authors:  B E Hayward; A Barlier; M Korbonits; A B Grossman; P Jacquet; A Enjalbert; D T Bonthron
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

6.  Activation of Janus kinase/signal transducer and activator of transcription 3 pathway by growth hormone-releasing hormone.

Authors:  Agnieszka Siejka; Andrew V Schally; Nektarios Barabutis
Journal:  Cell Mol Life Sci       Date:  2009-12-13       Impact factor: 9.261

7.  Differential pulsatile secretagogue control of GH secretion in healthy men.

Authors:  Catalina Norman; John Miles; Cyril Y Bowers; Johannes D Veldhuis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

Review 8.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

9.  Gonadal status and body mass index jointly determine growth hormone (GH)-releasing hormone/GH-releasing peptide synergy in healthy men.

Authors:  Remberto C Paulo; Mihaela Cosma; Cacia Soares-Welch; Joy N Bailey; Kristi L Mielke; John M Miles; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

10.  DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas.

Authors:  Anat Ben-Shlomo; Nan Deng; Evelyn Ding; Masaaki Yamamoto; Adam Mamelak; Vera Chesnokova; Artak Labadzhyan; Shlomo Melmed
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.